OTC Markets OTCQB - Delayed Quote USD

Satellos Bioscience Inc. (MSCLF)

Compare
0.5600 -0.0312 (-5.28%)
At close: October 18 at 4:00 PM EDT
Loading Chart for MSCLF
DELL
  • Previous Close 0.5912
  • Open 0.5110
  • Bid 0.5294 x --
  • Ask 0.6138 x --
  • Day's Range 0.5110 - 0.6183
  • 52 Week Range 0.2200 - 0.6183
  • Volume 9,500
  • Avg. Volume 12,370
  • Market Cap (intraday) 65.725M
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.49

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

satellos.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MSCLF

View More

Performance Overview: MSCLF

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MSCLF
72.31%
S&P/TSX Composite index
18.44%

1-Year Return

MSCLF
93.10%
S&P/TSX Composite index
26.05%

3-Year Return

MSCLF
55.02%
S&P/TSX Composite index
18.61%

5-Year Return

MSCLF
66.27%
S&P/TSX Composite index
51.11%

Compare To: MSCLF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MSCLF

View More

Valuation Measures

Annual
As of 10/18/2024
  • Market Cap

    65.74M

  • Enterprise Value

    31.93M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.00

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.20%

  • Return on Equity (ttm)

    -58.84%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -23.05M

  • Diluted EPS (ttm)

    -0.1400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    27.7M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -11.98M

Research Analysis: MSCLF

View More

Company Insights: MSCLF

Research Reports: MSCLF

View More

People Also Watch